Ropes & Gray Advises TPG Capital in a Definitive Purchasing Agreement with Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC, one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, and Impax Laboratories, Inc., a specialty pharmaceutical company, today announced they have entered into a definitive business combination in an all-stock transaction. Amneal Holdings members will own 75% and Impax shareholders will own 25% of the new company’s pro forma shares. The combined company Amneal Pharmaceuticals, Inc. will rank as the fifth largest genetics business in the United States by gross revenue and a growing, high-margin specialty franchise.
In connection with the transaction, Amneal Holdings members have entered into definitive purchase agreements with select institutional investors, including TPG Capital. The transaction is expected to close in the first half of 2018, subject to customary closing conditions.
The team was led by private equity partner Jason Freedman, securities & public companies partner Thomas Holden, mergers & acquisitions partner Paul Scrivano, business & securities litigation partner Christopher Green and associates Chau Le, Reed Harasimowicz and Emily Nagle.